Evidence map›Paper›PMID 28415996›Full record

ArticleMalaria journal2017

Travel and the emergence of high-level drug resistance in Plasmodium falciparum in southwest Uganda: results from a population-based study.

Caroline A Lynch, Richard Pearce, Hirva Pota, Connie Egwang, Thomas Egwang, Amit Bhasin, Jonathan Cox, Tarekegn A Abeku, Cally Roper

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. A NovelmedRxiv : the preprint server for health sciences · 2025
    Article
  2. Wellcome open research · 2024
    Article
  3. Article
  4. Article
  5. Advances and roadblocks in the treatment of malaria.British journal of clinical pharmacology · 2022
    Review
  6. Article
  7. High Frequency Mutations inFrontiers in cellular and infection microbiology · 2021
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Caroline A LynchFaculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK. Caroline.Lynch@lshtm.ac.uk.
Richard PearceFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Hirva PotaFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Connie EgwangMedical Biotechnology Laboratories, Kampala, Uganda.
Thomas EgwangMedical Biotechnology Laboratories, Kampala, Uganda.
Amit BhasinFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Jonathan CoxFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Tarekegn A AbekuMalaria Consortium, London, UK.
Cally RoperFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
London School of Hygiene & Tropical Medicine · GBMalaria Consortium · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe I164L mutation on the dhfr gene confers high level resistance to sulfadoxine-pyrimethamine (SP) but it is rare in Africa except in a cluster of reports where prevalence >10% in highland areas of southwest Uganda and eastern Rwanda. The occurrence of the dhfr I164L mutation was investigated in community surveys in this area and examined the relationship to migration.

methodsA cross-sectional prevalence survey was undertaken in among villages within the catchment areas of two health facilities in a highland site (Kabale) and a highland fringe site (Rukungiri) in 2007. Sociodemographic details, including recent migration, were collected for each person included in the study. A total of 206 Plasmodium falciparum positive subjects were detected by rapid diagnostic test; 203 in Rukungiri and 3 in Kabale. Bloodspot samples were taken and were screened for dhfr I164L.

resultsSequence analysis confirmed the presence of the I164L mutations in twelve P. falciparum positive samples giving an estimated prevalence of 8.6% in Rukungiri. Of the three parasite positive samples in Kabale, none had I164L mutations. Among the twelve I164L positives three were male, ages ranged from 5 to 90 years of age. None of those with the I164L mutation had travelled in the 8 weeks prior to the survey, although three were from households from which at least one household member had travelled during that period. Haplotypes were determined in non-mixed infections and showed the dhfr I164L mutation occurs in both as a N51I + S108N + I164L haplotype (n = 2) and N51I + C59R + S108N + I164L haplotype (n = 5). Genotyping of flanking microsatellite markers showed that the I164L occurred independently on the triple mutant (N51I, C59R + S108N) and double mutant (N51I + S108N) background.

conclusionsThere is sustained local transmission of parasites with the dhfr I164L mutation in Rukungiri and no evidence to indicate its occurrence is associated with recent travel to highly resistant neighbouring areas. The emergence of a regional cluster of I164L in SW Uganda and Rwanda indicates that transmission of I164L is facilitated by strong drug pressure in low transmission areas potentially catalysed in those areas by travel and the importation of parasites from relatively higher transmission settings.

Indexed as

Drug ResistanceMutation, MissenseTravelAdolescentAdultAgedAged, 80 and overChildChild, PreschoolCross-Sectional StudiesFemaleGene FrequencyHaplotypesHumansInfantInfant, NewbornTetrahydrofolate DehydrogenasedhfrDrug resistanceMalariaMigrationSulfadoxine–pyrimethamine (SP)Travel

Identifiers

PMID28415996
PMCPMC5392983
OpenAlexW2605859870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.